NCT05136677
Recruiting
November 29, 2021
May 12, 2022
Brief summary:
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
N/A
Arm | Intervention/treatment |
---|---|
Experimental: Arm A |
Biological: Nivolumab Specified dose on specified days Biological: Ipilimumab Specified dose on specified days |
Experimental: Arm B |
Drug: Pemetrexed Specified dose on specified days Drug: Cisplatin Specified dose on specified days Drug: Carboplatin Specified dose on specified days |
Inclusion Criteria: Histologically proven diagnosis of Malignant Pleural Mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology Must have advanced unresectable disease that is not amenable to therapy with curative intent (surgery with or without chemotherapy) Available tumor samples for centralized testing Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Measurable disease Exclusion Criteria: Primitive peritoneal, pericardial, testis or tunica vaginalis mesothelioma Brain metastasis, except if surgically resected or treated with stereotaxic radiotherapy Prior therapy for MPM (including chemotherapy, radical pleuropneumonectomy and non-palliative radiotherapy) Other protocol-defined inclusion/exclusion criteria apply
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.
China, Beijing
Local Institution
Beijing
China, Heilongjiang
Local Institution
Harbin
China, Henan
Local Institution
Zhengzhou
China, Hunan
Local Institution
Changsha
China, Hunan
Local Institution - 0005
Changsha
China, Jiangsu
Local Institution - 0015
Yangzhou
China, Jilin
Local Institution
Changchun
China, Liaoning
Local Institution
Shen Yang
China, Liaoning
Local Institution
Shenyang
China, Liaoning
Local Institution
Shenyang
China, Shanghai
Local Institution
Shanghai
China, Tianjin
Local Institution - 0007
Tianjin
China, Tianjin
Local Institution - 0018
Tianjin
China, Yunnan
Local Institution
Kunming
China, Zhejiang
Local Institution
Hangzhou
China, Zhejiang
Local Institution
Hangzhou
China, Zhejiang
Local Institution
Hangzhou
China, Zhejiang
Local Institution
Ningbo
China, Zhejiang
Local Institution
Ningbo
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb